



ANDA 202240

APPROVAL LETTER

Lupin Pharmaceuticals, Inc.
U.S. Agent for Lupin Limited
111 South Calvert St.
Harborplace Tower, 24th Floor
Baltimore, Maryland 21202
Attention: Dr. William McIntyre
Senior Vice President - Regulatory Affairs

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated September 30, 2010 and received October 6, 2010, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), for Celecoxib Capsules, 100 mg, 200 mg and 400 mg.

Reference is also made to the letter issued by this office on October 29, 2014, granting final approval to your Celecoxib Capsules, 50 mg, and granting tentative approval to your Celecoxib Capsules, 100 mg, 200 mg and 400 mg, and to your amendment dated March 5, 2015.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the **ANDA is approved**, effective on the date of this letter. The Division of Bioequivalence has determined your Celecoxib Capsules, 100 mg, 200 mg, and 400 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Celebrex Capsules of GD Searle LLC (Searle). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA.

The RLD upon which you have based your ANDA, Searle's Celebrex Capsules, 100 mg, 200 mg and 400 mg, is subject to periods of patent protection. As noted in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"), U.S. Patent No. 5,760,068 (the '068 patent) and its reissue, U.S. Patent No. RE44,048 (the 'RE048 patent) are scheduled to expire (with pediatric exclusivity added) on December 2, 2015.

Your ANDA contains paragraph IV certifications to each of the patents under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Celecoxib Capsules, 100 mg, 200 mg and 400 mg, under this ANDA. You have notified the agency with respect to the '068 patent that

Lupin Limited (Lupin) complied with the requirements of section 505(j)(2)(B) of the FD&C Act, and that no action for infringement was brought against Lupin within the statutory 45-day period.

You have also notified the agency that litigation was initiated against Lupin for infringement of 'RE048 patent within the statutory 45-day period in the United States District Court for the Eastern District of Virginia [G.D. Searle LLC and Pfizer Asia Pacific PTE. LTD. v. Lupin Pharmaceuticals, Inc., Teva Pharmaceuticals Usa, Inc., Mylan Pharmaceuticals Inc., Watson Laboratories, Inc., Apotex Inc., And Apotex Corp., Civil Action No. 2:13-cv-00121-AWA-LRL]. You have also notified the agency that the court decided that the 'RE048 patent is invalid. FDA is approving your application during the pediatric exclusivity period associated with both the '068 and 'RE048 patents because courts have ruled that each of these patents is invalid. The '068 patent was found to be invalid by the Federal Circuit. The court's mandate reflecting this decision was issued on May 6, 2008. Approval of your ANDA during the pediatric exclusivity periods associated with the '068 and 'RE048 patents is consistent with FDA's previous conclusion that "if in a paragraph IV litigation a court determines that a patent is *invalid* or *not infringed*, pediatric exclusivity will not bar approval of that applicant's ANDA."¹

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

¹ See Docket No. FDA 2007-P-0351 (June 10, 2008) (addressing pediatric exclusivity for Amlodipine Besylate Tablets).

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

Carol A. Holquist -S

Digitally signed by Carol A. Holquist -S
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People,
0.9.2342.19200300.100.1.1=1300052464, cn=Carol A. Holquist -S
Date: 2015.06.09 17:21:09 -04'00'

Carol A. Holquist, RPh
Acting Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research